Trill Impact, the firm that last year raised a debut fund of €900 million, has unveiled two investments in the last week, including its first venture capital deal. The firm led an SKr240 million (€43 million; $46 million) funding round in Swedish late-stage biopharmaceutical company Cinclus Pharma.
The company is developing linaprazan glurate, which could be used in the treatment of severe stomach acid-related disorders. “We see this as a great example of a company where commercial opportunity and impact go hand in hand,” said Nina Rawal, partner and co-head of ventures, in a statement.
Trill has also acquired a majority stake in Raksystems, which offers building inspections and services, “green building services” and related renovation and new construction projects. Press release here.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: